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Background:  We  examined  the implication  of the  revised  platform  of TAXUS  Liberté  (TAXUS-Lib;  Boston
Scientiﬁc,  Natick,  MA,  USA)  from  TAXUS  Express  (TAXUS-Exp;  Boston  Scientiﬁc)  stents,  after  stent  place-
ments  in a daily  practice  environment,  on midterm  clinical  and  angiographic  outcomes.
Methods and results:  By  adjusting  historically  different  baselines  with  propensity  score  matching  analysis
in  1358  de novo native  coronary  stenoses,  the  incidence  of the clinical  safety  endpoint  (700-day  cardiac
death,  nonfatal  recurrent  myocardial  infarction,  and  deﬁnite  stent  thrombosis)  after  placement  of  TAXUS-
Lib  (0.60%;  mean  follow-up,  683 ± 64 days)  was  not  signiﬁcantly  different  from  that  in the  TAXUS-Exp
group  (1.20%;  677  ± 96 days,  p =  0.182).  Cardiac  dysfunction  (ejection  fraction  of left ventricle  less  than
40%)  was the  predictor  of primary  endpoint  [odds  ratio  (OR),  17.8;  95%  CI,  4.39–71.9;  p  <  0.001].  In  the
baseline-adjusted  angiographic  followed-up  lesions  (n = 443  in  each  arm),  the incidence  of  secondary
endpoint  [binary  in-stent  restenosis:  percent  diameter  stenosis  (%DS)  >50%  at  the  follow-up  angiography]
in  the  TAXUS-Lib  group  (11.3%)  was  not  signiﬁcantly  different  from  that  in  the TAXUS-Exp  group  (13.5%,
p  =  0.368).  TAXUS-Exp  was  not  the  predictor  of secondary  endpoint  (OR,  1.20;  95%  CI, 0.77–1.85; p  = 0.424).
Conclusions:  The  midterm  clinical  and  angiographic  outcomes  after  placement  of the  new  TAXUS-Lib  stent
for  de  novo coronary  stenosis  in  a daily  practice  environment  were statistically  equivalent  compared  to
the  former  TAXUS-Exp.
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Coronary stent technology has been advancing, and new drug-
luting stents (DESs) are anticipated to improve clinical and
ngiographic outcomes. The TAXUS Liberté stent (Boston Scien-
iﬁc, Natick, MA,  USA) was designed with a thinner strut and
ore even strut spacing to provide more uniform drug distri-
ution while having identical polymer, drug dosage, and release
inetics with the older paclitaxel-eluting TAXUS Express stent
Boston Scientiﬁc) [1]. Intravascular ultrasonography (IVUS) [2]
nd optical coherence tomography (OCT) [3] have shown homoge-
eous, but suppressed, neointima growth across the full length of
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TAXUS Liberté compared with TAXUS Express. The TAXUS ATLAS
trial [4] showed the noninferiority of TAXUS Liberté in terms of
clinical and angiographic outcomes when compared with TAXUS
Express, despite the increased lesion complexity in patients treated
with TAXUS Liberté. However, both the safety of TAXUS Liberté
and its ability to improve angiographic outcomes have not been
fully understood in the baseline-adjusted cohort and in Japanese
daily practice environment, where the incidences of severe cardiac
events including deﬁnite stent thrombosis [5] are lesser than in
Western countries [6–9].
In  the present study, we sought to examine how the IVUS- [2]
and OCT- [3] proven neointima suppression in patients treated with
TAXUS Liberté resulted in statistical improvements in midterm out-
comes after placements in a daily practice environment, including
high-risk complex baselines. For this purpose, the 700-day clinical
outcome and angiographic outcome of TAXUS Liberté approxi-
mately at 1 year after placement for de novo native coronary
stenoses were compared with those of TAXUS Express by adjusting
the historically different baselines.
vier Ltd. All rights reserved.
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ethods
tudy design and population
The  present study was a retrospective, nonrandomized, single-
enter study performed at Saitama Cardiovascular Respiratory
enter. The retrospective examination was performed in November
012. The selection of stent [sirolimus-eluting stent (SES); Cypher
x Velocity; Cordis Corp., Miami, FL, USA; TAXUS stent, or other
ESs, or bare-metal stents (BMS); after TAXUS Express approval in
ay  2007], use of percutaneous coronary intervention (PCI) modal-
ties such as IVUS and rotablator, duration of thienopyridine agent
dministration, and indication for follow-up coronary angiography
fu-CAG) were not randomized.
The inclusion criteria were lesions with de novo stenosis in
ative coronary arteries that were successfully and exclusively
reated by elective TAXUS Express or TAXUS Liberté as our previ-
us studies [10,11]. From May  2007 to February 2009, the number
f lesions successfully stented with TAXUS Express, SES, and BMS
ere 682, 384, and 62 lesions, respectively. From February 2009
o April 2011, the number of lesions successfully stented with
AXUS Liberté, other DESs, and BMS  were 753, 339, and 118 lesions,
espectively.
rocedures for stenting and antiplatelet therapy
All patients were informed of the necessity of PCI and sten-
ing, and informed consent was obtained [10,11]. The stents were
mplanted by visual angiographic estimation to cover the entire
aseline lesion under the guidance of IVUS (Table 1). When fur-
her stent dilation was needed, high-pressure ballooning with a
oncompliant balloon was  typically performed.
Periprocedural antiplatelet therapy was conducted as previ-
usly reported [10,11]. When elective PCI was planned, aspirin
81–100 mg)  and ticlopidine (200 mg)  were orally administered
pproximately 10 days before the index procedure. After the pro-
edure, ticlopidine (200 mg/day) or clopidogrel (75 mg/day) were
rescribed for a minimum of 12 weeks, although these prescrip-
ions were not prospectively randomized as mentioned above.
ollow-up  angiography and quantitative coronary artery
valuation
The  angiographic outcomes at the fu-CAG through October 2012
ere included in the analyses. The fu-CAG was planned at approx-
mately 8–18 months after the stenting procedure. The rate of
u-CAG was 66.3% (452 among 682 cases) in the TAXUS Express
roup and 72.9% in the TAXUS Liberté (549 among 753 cases) group
with signiﬁcant difference; p < 0.01).
The  quantitative coronary artery parameters were measured
sing a test circulatory cardiovascular network system (CAAS-2 or
AAS-5 system; the Netherlands), as described previously [10,11].
alues were obtained at 3 time points: before PCI (preprocedu-
al), immediately after successful PCI (postprocedural), and during
he chronic phase (follow-up). The measurements included the in-
tent minimal lumen diameter (MLD), percent diameter stenosis
%DS), and reference diameter (RD). In cases showing occlusions
t the preprocedural and follow-up stages, the MLD  was  consid-
red as 0 and the %DS as 100%. Additionally, we  calculated the
cute gain (postprocedural MLD  minus preprocedural MLD) and
ate loss (postprocedural MLD  minus MLD  at the chronic phase).
inary in-stent restenosis (binary restenosis) was deﬁned as a %DS
50% at the fu-CAG. In-stent restenosis (ISR) was  divided into
ocal (lesion length at chronic phase ≥ 10 mm)  (type-1) and dif-
use (<10 mm)  (types 2–4) types [12]. The percentage of types 2–4
SR in the binary restenosis (types 2–4 ISR/binary restenosis) iniology 62 (2013) 289–295
the  TAXUS-Exp group was compared with that of the TAXUS-Lib
group. Incidence of target lesion revascularization (TLR) after fu-
CAG including the deﬁnite stent thrombosis [5] was compared.
TLR was  decided mainly by visual estimation of angiographic out-
come.
Estimated endpoints
The  safety (primary) endpoint of the clinical outcome was a
cardiac-event composite comprising cardiac death without a deﬁ-
nite non-cardiac cause (cardiac death), nonfatal re-MI, and deﬁnite
(early, late, and very late) stent thrombosis [5] within 700 days
after the index procedure. The efﬁcacy (secondary) endpoints of
the angiographic outcome were deﬁned as the incidences of binary
restenosis (deﬁned above) at the fu-CAG.
Statistical analyses
Baseline  characteristic variables are expressed as the
mean ± standard deviation (SD). The variables and endpoints
in the TAXUS Liberté group were compared with those in the
TAXUS Express group by using unpaired t-tests for continuous
values, and 2 or Fisher’s tests for categorical values. A propensity
score matching analysis was performed to adjust the baseline
variables related to clinical and angiographic outcomes between
the 2 groups as our former report [13,14]. Log-rank test and Cox
proportional hazard model were used to compare the cumulative
primary endpoint-free ratios of the 2 groups after the adjust-
ment. In order to deﬁne the impact of TAXUS stent on secondary
endpoints, logistic regression analysis was done including the
adjusted variables. A p-value of <0.05 was  considered statistically
signiﬁcant. Stata for Windows version 12.1 (StataCorp, College
Station, TX, USA) was  used for statistical analyses.
Results
Baseline characteristics and incidence of primary endpoint
Table  1 shows the baseline characteristics and the clinical
outcomes in the TAXUS-Lib group (n = 753) and the TAXUS-Exp
group (n = 682). Among the 31 variables, the percentages of prior
myocardial infarction (MI) (34.4%), chronic total occlusion (CTO)
(18.3%), and IVUS (98.9%) in the TAXUS-Lib group were signiﬁ-
cantly different from those in the TAXUS-Exp group (47.1%, 8.9%,
and 96.5%, respectively) (p < 0.001, p = 0.001, and p = 0.002, respec-
tively). The mean values of stent diameter (3.21 ± 0.41 mm), stent
length (38.7 ± 21.8 mm),  preprocedural MLD  (0.82 ± 0.54 mm),
acute gain (1.71 ± 0.59 mm), postprocedural %DS (10.5 ± 8.70),
and postprocedural RD (2.85 ± 0.55 mm)  in the TAXUS-Lib group
were signiﬁcantly different from those in the TAXUS-Exp group
(3.11 ± 0.42 mm,  34.3 ± 20.6 mm,  0.97 ± 0.53 mm,  1.61 ± 0.59 mm,
11.6 ± 8.56, and 2.95 ± 0.58 mm,  respectively) (p < 0.001, p = 0.036,
p < 0.001, p < 0.001, p = 0.015, and p = 0.001, respectively).
The incidences of the primary endpoint and its related variables
in the TAXUS-Lib group were not signiﬁcantly different from those
in the TAXUS-Exp group. The incidence of non-cardiac death in the
TAXUS-Lib group (0.93%) was signiﬁcantly lower than that in the
TAXUS-Exp group (2.35%, p = 0.012).
Adjusted  baseline characteristics and incidence of primary
endpointTable  2 shows the adjusted baseline characteristics and the inci-
dence of the primary endpoint in the TAXUS-Lib and TAXUS-Exp
groups (n = 679 in each arm). The incidence of the primary endpoint
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Table  1
Baseline characteristics and incidence of the primary endpoint.
n TAXUS Liberté
753
TAXUS  Express
682
p-Value
Age (year) 67.7 ± 10.5 67.2 ± 10.0 0.356
Male  (%) 80.2 79.2 0.627
Diabetes  (%) 44.2 42.1 0.414
Insulin  (%) 5.8 4.4 0.217
Hemodialysis  (%) 2.5 1.9 0.429
Prior  MI  (%) 34.4 47.1 <0.001
Cardiac  dysfunction (%) 4.9 4.3 0.700
LAD  (%) 37.1 37.0 0.968
LCX  (%) 25.9 28.4 0.278
LMT  (%) 2.4 1.8 0.404
RCA  (%) 34.7 32.8 0.467
Severe  calciﬁcation (%) 13.5 11.1 0.168
RCA  ostium (%) 2.1 2.5 0.642
LAD  ostium (%) 9.8 8.1 0.244
LCX  ostium (%) 4.4 4.4 0.988
Main  branch of bifurcation 2-stent (%) 6.5 5.3 0.325
Side  branch of bifurcation 2-stent (%) 6.9 5.9 0.422
CTO  (%) 18.3 8.9 <0.001
IVUS  (%) 98.9 96.5 0.002
Rotablator  (%) 3.9 6.0 0.058
Number  of stent 1.44 ± 0.70 1.41 ± 0.70 0.418
Diameter  of stent (mm) 3.21 ± 0.41 3.11 ± 0.42 <0.001
Length  of stent (mm)  38.7 ± 21.8 34.3 ± 20.6 0.036
Maximum  pressure (atm) 18.2 ± 2.95 18.1 ± 3.04 0.377
Direct  stenting (%) 24.2 28.0 0.098
Preprocedural  MLD  (mm)  0.82 ± 0.54 0.97 ± 0.53 <0.001
Preprocedural  %DS 69.5 ± 18.7 64.6 ± 17.3 0.941
Postprocedural  MLD  (mm)  2.53 ± 0.45 2.58 ± 0.46 0.377
Acute  gain (mm) 1.71 ± 0.59 1.61 ± 0.59 <0.001
Postprocedural  %DS 10.5 ± 8.70 11.6 ± 8.56 0.015
Postprocedural  RD (mm)  2.85 ± 0.55 2.95 ± 0.58 0.001
Clinical  observation duration (days) 680 ± 61 671 ± 112 0.062
Primary  endpoint (%) 0.53 1.17 0.182
Cardiac  death (%) 0.53 1.03 0.281
Nonfatal-MI  (%) 0 0 1.000
Deﬁnite  stent thrombosis (%) 0.13 0.15 0.944
Non-cardiac  death (%) 0.93 2.35 0.012
The baseline characteristics and the clinical outcomes in the TAXUS Liberté group (n = 753) and the TAXUS Express group (n = 682) are shown. The deﬁnitions of the variables
and  estimated outcomes are as follows: the variables used as baseline characteristics, in particular, patient, angiographic, and procedural characteristics and QCA were
as  follows: age at the index procedure; male sex; diabetes status (determined by blood tests for plasma glucose and hemoglobin A1c); insulin use; hemodialysis, prior
myocardial infarction (MI), and cardiac dysfunction (left ventricle ejection fraction of <40% as evaluated by ultrasonography or left ventriculogram); lesion location (left
anterior descending [LAD], left circumﬂex [LCX], left main trunk [LMT], and right coronary arteries [RCA]); severe calciﬁcation (estimated using angiography and intravascular
ultrasound [IVUS]); RCA ostium, LAD ostium, and LCX ostium (ostium lesions of the RCA, LAD, and LCX); main and side branches after treatment with the bifurcation 2-stent
technique (main branch of bifurcation 2-stent, side branch of bifurcation 2-stent); chronic total occlusion (CTO); IVUS (IVUS availability during percutaneous coronary
intervention); rotablator use (rotablator); number of stents (number of implanted stents per lesion); diameter of stent (maximum diameter of the balloon used to dilate
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n the TAXUS-Lib group (0.60%) was not signiﬁcantly different from
hat in the TAXUS-Exp group (1.20%, p = 0.182).
umulative primary endpoint-free ratios and the predictor of
rimary  endpoint
After  adjusting the baseline values as shown in Table 2, the
umulative primary endpoint-free ratio in the TAXUS-Lib group
as not signiﬁcantly different from that in the TAXUS-Exp group
data not shown; p = 0.246, by log-rank test).
Cardiac dysfunction was the predictor of primary endpoint in
ox proportional hazard analysis [hazard ratio (HR): 17.8, 95% con-
dential interval (95% CI), 4.39–71.9, p < 0.001]. TAXUS-Exp was
ot signiﬁcantly related to the primary endpoint (HR, 1.72; 95%
I, 0.45–6.53, p = 0.80) (Table 3).aseline  characteristics and incidences of secondary endpoints
Table  4 shows the baseline characteristics and angiographic
utcomes in the TAXUS-Lib group (n = 549) and the TAXUS-Expf overlap); maximum pressure at the maximum inﬂation diameter of the balloon;
tion (from presentation until censored). The primary endpoint was deﬁned in the
 diameter stenosis; RD, reference diameter.
group  (n = 452). Among the 34 variables, the percentages of
prior MI  (31.7%), CTO (17.5%), IVUS (99.1%), rotablator (3.1%),
and direct stenting (24.6%) in the TAXUS-Lib group were sig-
niﬁcantly different from those in the TAXUS-Exp group (47.3%,
9.1%, 96.2%, 6.2%, and 31.2%, respectively) (p < 0.001, p < 0.001,
p = 0.002, p = 0.019, and p = 0.020, respectively). The mean val-
ues of stent diameter (3.21 ± 0.42 mm), preprocedural MLD
(0.81 ± 0.51 mm), preprocedural %DS (69.5 ± 18.1), postprocedural
MLD (2.52 ± 0.44 mm),  acute gain (1.70 ± 0.58 mm),  postproce-
dural %DS (10.9 ± 8.82), postprocedural RD (2.85 ± 0.55 mm),
and interval for fu-CAG (334 ± 87 mm)  in the TAXUS-Lib
group were signiﬁcantly different from those in the TAXUS-
Exp group (3.10 ± 0.42 mm,  0.99 ± 0.54 mm,  64.2 ± 17.4,
2.58 ± 0.46 mm,  1.59 ± 0.60 mm,  11.9 ± 8.58, 2.95 ± 0.56 mm,
and 347 ± 90 mm,  respectively) (p < 0.001, p < 0.001, p < 0.001,
p = 0.036, p = 0.003, p = 0.011, p = 0.005, and p = 0.021, respec-
tively).
The incidences of the secondary endpoints, types 2–4 ISR/binary
restenosis, and TLR in the TAXUS-Lib group were not signiﬁcantly
different from those in the TAXUS-Exp group.
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Table  2
Adjusted baseline characteristics and incidence of the primary endpoint.
n TAXUS Liberté
679
TAXUS  Express
679
p-Value
Age (year) 67.9  ± 10.1 67.2 ± 10.0 0.121
Male  gender (%) 80.3 79.2 0.693
Diabetes  (%) 39.0 42.3 0.249
Hemodialysis  (%) 3.2 1.9 0.176
Prior  MI  (%) 45.8 47.0 0.681
Cardiac  dysfunction (%) 3.4 4.3 0.489
Severe  calciﬁcation (%) 12.2 11.2 0.611
CTO  (%) 8.8 9.0 0.923
Rotablator  (%) 7.1 5.9 0.586
Number  of stent 1.40 ± 0.68 1.41 ± 0.69 0.695
Diameter  of stent (mm)  3.10 ± 0.40 3.11 ± 0.42 0.962
Length  of stent (mm) 33.6 ± 19.3 34.3 ± 20.6 0.838
Preprocedural  MLD  (mm) 0.97 ± 0.49 0.97 ± 0.53 0.920
Preprocedural  %DS 64.7 ± 15.8 64.6 ± 17.4 0.924
Postprocedural  MLD (mm)  2.58 ± 0.42 2.58 ± 0.47 0.953
Postprocedural  %DS 11.5 ± 8.4 11.6 ± 8.57 0.894
Postprocedural  RD (mm) 2.93 ± 0.53 2.94 ± 0.58 0.913
Clinical  observation duration (day) 683 ± 64 677 ± 96 0.246
Primary  endpoint (%) 0.60 1.20 0.182
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dhe adjusted baseline characteristics and the incidence of the primary endpoint 
eﬁnitions of the variables and estimated outcomes are described in Table 1. MI,  m
ercent  diameter stenosis; RD, reference diameter.
djusted baseline characteristics and incidences of secondary
ndpoints
Table  5 shows the adjusted baseline characteristics and the inci-
ences of secondary endpoints in the TAXUS-Lib and TAXUS-Exp
roups (n = 443 in each arm). The incidences of the secondary end-
oints, types 2–4 ISR/binary restenosis, and TLR in the TAXUS-Lib
roup were not signiﬁcantly different from those in the TAXUS-Exp
roup.
redictors of binary restenosis in adjusted baselines
In Table 6, predictors of binary restenosis in adjusted baselines
hown in Table 5 are shown. Preprocedural %DS [odds ratio (OR),
.94; 95% CI, 0.92–0.98; p < 0.001], preprocedural MLD  (OR, 0.15;
5% CI, 0.05–0.98; p = 0.001), length of stent (OR, 1.05; 95% CI,
.02–1.09; p = 0.001), age (OR, 1.03; 95% CI, 1.01–1.06; p = 0.010),
ight coronary artery (OR, 2.54; 95% CI, 1.22–5.30; p = 0.013),
nd left anterior descending artery (OR, 2.19; 95% CI, 1.09–4.36;
 = 0.027) were the signiﬁcant predictors of binary restenosis,
able 3
redictors of primary endpoint.
Hazard ratio 
TAXUS Express 1.72 
Age  1.04 
Male  gender 1.03 
Diabetes  3.32 
Prior  MI  0.99 
Cardiac  dysfunction 17.8 
Severe  calciﬁcation 5.36 
CTO  13.4 
Rotablator  0.037 
Number  of stent 0.21 
Diameter  of stent 0.15 
Length  of stent 1.06 
Preprocedural  MLD  9.59 
Preprocedural  %DS 1.03 
Postprocedural  MLD 2.41 
Postprocedural  %DS 0.95 
Postprocedural  RD 0.24 
redictors of primary endpoint analyzed using Cox proportional hazard model in the bas
ingle  predictor of primary endpoint. MI,  myocardial infarction; CTO, chronic total occlus
iameter. TAXUS Liberté and TAXUS Express groups (n = 679 in each arm) are shown. The
dial infarction; CTO, chronic total occlusion; MLD, minimal lumen diameter; %DS,
but  TAXUS-Exp was not (OR, 1.20; 95% CI, 0.77–1.85; p = 0.424)
(Table 6).
Discussion
The  important issue in estimating the safety of novel, improved
coronary stents is the lower, or at least noninferior, clinical
incidence of the safety endpoint compared with the use of
older-generation stents. However, in Japan, severe cardiac events,
including deﬁnite stent thrombosis [5], are infrequent compared
with Western countries in not only elective but also emergent cases
[6–9,13]. Our results demonstrated the favorable midterm safety of
both TAXUS-Exp and TAXUS-Lib after placements in a daily practice
environment, including various consistent predictors of severe car-
diac events and restenosis (Tables 1 and 2): >40% of lesions were in
patients with diabetes [15]; approximately 10% of lesions displayed
calciﬁcation [6,16]; >10% were ostial lesions [17]; diffuse lesions
were treated with long stents (mean length >34 mm)  [18,19]; and
the bifurcation 2-stent technique was used in approximately 5%
95% CI p-Value
0.45–6.53 0.80
0.97–1.11 0.26
0.36–9.32 0.47
0.87–12.6 0.08
0.28–3.50 0.99
4.39–71.9 <0.001
0.76–37.9 0.09
0.998–180 0.05
0.000–29.0 0.33
0.015–3.08 0.26
0.018–1.19 0.07
0.96–1.16 0.25
0.51–180 0.13
0.92–1.16 0.57
0.000–129 0.84
0.72–1.24 0.68
0.000–849 0.73
eline adjusted cohort as shown in Table 2 was  shown. Cardiac dysfunction was the
ion; MLD, minimal lumen diameter; %DS, percent diameter stenosis; RD, reference
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Table  4
Baseline characteristics and incidences of the secondary endpoints.
n TAXUS Liberté
549
TAXUS  Express
452
p-Value
Age (year) 66.3 ± 10.1 66.6 ± 9.5 0.629
Male  (%) 81.1 82.5 0.550
Diabetes  (%) 45.7 44.7 0.745
Insulin  (%) 4.9 4.4 0.714
Hemodialysis  (%) 2.0 0.9 0.147
Prior  MI  (%) 31.7 47.3 <0.001
Cardiac  dysfunction (%) 4.7 2.7 0.086
LAD  (%) 37.9 37.2 0.815
LCX  (%) 25.9 27.2 0.631
LMT  (%) 2.7 2.2 0.600
RCA  (%) 33.5 33.4 0.971
Severe  calciﬁcation (%) 12.0 11.1 0.637
RCA  ostium (%) 1.5 2.0 0.515
LAD  ostium (%) 10.2 8.4 0.333
LCX  ostium (%) 4.7 4.4 0.815
Main  branch of bifurcation 2-stent (%) 7.3 5.5 0.262
Side  branch of bifurcation 2-stent (%) 7.7 6.6 0.537
CTO  (%) 17.5 9.1 <0.001
IVUS  (%) 99.1 96.2 0.002
Rotablator  (%) 3.1 6.2 0.019
Number  of stent 1.42 ± 0.67 1.41 ± 0.68 0.816
Diameter  of stent (mm) 3.21 ± 0.42 3.10 ± 0.42 <0.001
Length  of stent (mm)  34.4 ± 21.6 34.1 ± 20.3 0.868
Maximum  pressure (atm) 18.2 ± 2.93 18.1 ± 3.06 0.564
Direct  stenting (%) 24.6 31.2 0.020
Preprocedural  MLD  (mm)  0.81 ± 0.51 0.99 ± 0.54 <0.001
Preprocedural  %DS 69.5 ± 18.1 64.2 ± 17.4 <0.001
Postprocedural  MLD  (mm)  2.52 ± 0.44 2.58 ± 0.46 0.036
Acute  gain (mm) 1.70 ± 0.58 1.59 ± 0.60 0.003
Postprocedural  %DS 10.9 ± 8.82 11.9 ± 8.58 0.011
Postprocedural  RD (mm)  2.85 ± 0.55 2.95 ± 0.56 0.005
Follow  up MLD  (mm)  2.03 ± 0.64 2.11 ± 0.69 0.059
Late  loss (mm) 0.50 ± 0.63 0.46 ± 0.66 0.330
Follow  up %DS 26.9 ± 18.28 27.7 ± 18.3 0.502
Interval  for fu-CAG (day) 334 ± 87 347 ± 90 0.021
Binary  restenosis (%) 12.6 13.5 0.664
Types  2–4 ISR/binary restenosis (%) 60.9 55.7 0.553
Target  lesion revascularization (%) 12.6 11.9 0.766
The baseline characteristics and angiographic outcomes in the TAXUS Liberté group (n = 549) and the TAXUS Express group (n = 452) are shown. The deﬁnitions of the variables
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f lesions [17]. In the present cohort, cardiac dysfunction was the
ingle signiﬁcant predictor of severe cardiac events, which was
onsistent with the ﬁndings of a previous report [19] (Table 3).
owever, during a mean follow-up period of approximately 680
ays, the percentages of severe cardiac events after placements
f TAXUS-Exp or TAXUS-Lib (approximately 1.0%) were accept-
ble and more favorable than those reported in Western countries
20–22] (Tables 1 and 2). Speciﬁcally, the rate of severe cardiac
vents in Western studies was approximately 7.5–14.5% after 1
ear, and not only were some of the predictors analyzed in the
resent study not included in those studies but also the percent-
ges of patients with variables such as diabetes, calciﬁcation, ostial
esions, and use of the bifurcation 2-stent technique were much
igher in our study than in those Western studies [20–22]. Thus,
he present study ﬁrst showed the midterm safety of TAXUS-Lib
n a daily practice environment (with statistical safety similar to
hat of TAXUS-Exp) in Japanese patients by the baseline-adjusted
valuation of >1300 de novo native coronary stenosis lesions. There-
ore, since only a few studies have reported on the clinical course
f patients treated with TAXUS-Exp in Japan [9,10], the long-term
linical course should be carefully observed further after place-
ents of TAXUS-Lib and TAXUS-Exp.
On the basis of the established clinical safety as described above,
etter angiographic outcomes are the most anticipated issues after
he revision of the stent platform from TAXUS-Exp to TAXUS-Lib.; LAD, left anterior descending artery; LCX, left circumﬂex artery; LMT, left main
und; MLD, minimal lumen diameter; %DS, percent diameter stenosis; RD, reference
The  larger mean late loss of the present study (ranging from 0.46 to
0.50 mm)  (Table 2) compared to those in TAXUS ATLAS trial (ran-
ging from 0.41 to 0.42 mm)  [4] conﬁrmed the complexity of the
present study as above. The present study was the ﬁrst compar-
ing the angiographic outcomes of 2 TAXUS stents after placements
in a baseline adjusted daily practice environment cohort (Table 5).
As the result, TAXUS stent did not exert the statistical signiﬁcant
impacts on the late loss, binary restenosis, and TLR (Tables 5 and 6).
Thus, although the more uniform neointimal distribution by the
improved diffusion of paclitaxel to the vessel wall owing to the thin-
ner stent strut compared to the former TAXUS-Exp was  observed
by IVUS and OCT in relatively short segment stented lesions [1–3],
the advantage of TAXUS-Lib was not found to be the signiﬁcant
reductions in the late loss and the binary restenosis in the present
daily practice environment including a complex lesions (Table 5).
Thus, the present study could not conﬁrm the importance of the
stent platform in the improvement of angiographic outcomes. Thus,
this issue should be further conﬁrmed in sub-analyses, such as of
small vessel, patients with diabetes, long segment stented lesion,
and complex lesions evaluated for consistent predictors of cardiac
events, binary restenosis, and TLR of SES [10]. Furthermore, meta-
analysis collecting several reports would be needed to evaluate the
angiographic difference between the 2 TAXUS stents.
The  present study has several limitations that should be con-
sidered in interpreting the results. First, this is a retrospective,
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Table  5
Adjusted baseline characteristics and incidences of the secondary endpoints.
n TAXUS Liberté
443
TAXUS  Express
444
p-Value
Age (year) 66.7  ± 9.4 66.6 ± 9.4 0.798
Male  (%) 81.5 82.4 0.799
Diabetes  (%) 42.4 44.2 0.631
Insulin  (%) 2.5 4.3 0.201
Hemodialysis  (%) 1.1 0.9 0.739
Prior  MI  (%) 49.0 46.7 0.498
Cardiac  dysfunction (%) 3.6 2.7 0.557
LAD  (%) 37.0  37.0 1.000
RCA  (%) 33.0 33.2 0.944
Severe  calciﬁcation (%) 8.6 10.4 0.428
RCA  ostium (%) 1.1 2.0 0.424
LCX  ostium (%) 5.4 4.5 0.636
Side  branch of bifurcation 2-stent (%) 6.3 6.8 0.892
CTO  (%) 11.5 9.0 0.266
IVUS  (%) 97.7 97.3 0.832
Rotablator  (%) 4.1 5.4 0.291
Number  of stent 1.38 ± 0.66 1.40 ± 0.68 0.849
Diameter  of stent (mm)  3.12 ± 0.40 3.11 ± 0.42 0.543
Length  of stent (mm) 33.4 ± 20.8 34.1 ± 20.2 0.557
Direct  stenting (%) 33.9 31.4 0.460
Preprocedural  MLD  (mm) 1.01 ± 0.50 0.98 ± 0.52 0.380
Preprocedural  %DS 64.2 ± 15.5 64.4 ± 17.3 0.874
Postprocedural  MLD (mm)  2.60 ± 0.44 2.58 ± 0.46 0.248
Acute  gain (mm) 1.59 ± 0.56 1.60 ± 0.61 0.794
Postprocedural  %DS 12.3 ± 8.6 11.8 ± 8.6 0.400
Postprocedural  RD (mm)  2.99 ± 0.54 2.94 ± 0.55 0.107
Follow  up MLD  (mm)  2.12 ± 0.64 2.11 ± 0.69 0.950
Late  loss (mm)  0.50 ± 0.64 0.47 ± 0.66 0.219
Follow  up %DS 26.9  ± 16.5 27.7 ± 18.4 0.179
Interval  for fu-CAG (day) 347 ± 91 347 ± 90 0.895
Binary  restenosis (%) 11.3 13.5 0.368
Types  2–4 ISR/binary restenosis (%) 66.0 56.7 0.403
Target  lesion revascularization (%) 9.0 12.0 0.198
The adjusted baseline characteristics and incidences of secondary endpoints in the TAXUS Liberté and TAXUS Express groups (n = 443 in each arm) are shown. The deﬁnitions
of  the variables and estimated outcomes are described in the text and Table 1. MI, myocardial infarction; LAD, left anterior descending artery; LCX, left circumﬂex artery; RCA,
right  coronary artery; CTO, chronic total occlusion; IVUS, intravascular ultrasound; MLD, minimal lumen diameter; %DS, percent diameter stenosis; RD, reference diameter;
fu-CAG, follow-up coronary angiography; ISR, in-stent restenosis.
Table  6
Predictors of binary restenosis.
Odds ratio 95%CI p-Value
Preprocedural %DS 0.95 0.92–0.98 <0.001
Preprocedural  MLD  0.15 0.05–0.98 0.001
Length  of stent 1.05 1.02–1.09 0.001
Age  1.03 1.01–1.06 0.010
RCA  2.54 1.22–5.30 0.013
LAD  2.19 1.09–4.36 0.027
CTO  0.35 0.12–1.02 0.054
.
.
.
.
.
.
.
.
.
.
.
.
TAXUS  Express 1.20 0.77–1.85 0.424
.
.
.
.
.
.
.
.
.
.
.
.
Predictors of binary restenosis analyzed by logistic regression analysis in the baseline adjusted cohort as shown in Table 5 are shown. The ﬁrst 6 variables were the signiﬁcant
p S, per
L
n
(
n
g
H
l
p
b
T
e
eredictors, and the other variables including TAXUS Express were not signiﬁcant. %D
AD,  left anterior descending artery; CTO, chronic total occlusion.
onrandomized, and single-center analysis. The selection of stents
PES, BMS, or SES), and the choice of treatment (PCI or CABG) were
ot randomized. Second, the lower rate of fu-CAG in the TAXUS-Exp
roup might have also underestimated the efﬁcacy of TAXUS-Exp.
owever, the baseline adjustment of the characteristics of 443
esions in each arm would be enough to compare the angiogra-
hic outcomes. Third, the more details about the six predictors of
inary restenosis (Table 6) and the differential predictors of the 2
AXUS stents need to be further clariﬁed. In addition, the differ-
nce in the initial success rate during the procedure was  not fully
stimated. Furthermore, the duration of dual antiplatelet therapycent diameter stenosis; MLD, minimal lumen diameter; RCA, right coronary artery;
and  the choice of thienopyridine agent (ticlopidine or clopido-
grel) depended on the doctor’s judgment. However, there was no
increase in the number of cardiac events or deﬁnite stent throm-
bosis events (Tables 1 and 2). Finally, other predictors of cardiac
events, such as medications, renal dysfunction, and anemia, were
not examined.Conclusion
The TAXUS-Lib stent with a revised platform did not exert ben-
eﬁcial impact on the midterm clinical and angiographic outcomes
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